What is OrthoPediatrics' operating income?

OrthoPediatrics' total operating income in 2025 was -$39.24 million, based on the following breakdown: Total Gross Profit: $172.66 million Total Operating Expenses: $211.90 million

OrthoPediatrics (KIDS) Financials

$19.82 -0.63 (-3.08%)

Closing price 04:00 PM Eastern

Extended Trading

$19.83 +0.01 (+0.05%)

As of 04:10 PM Eastern

Compare

Annual Income Statements for OrthoPediatrics

This table shows OrthoPediatrics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-13	-12	-24	-12	-14	-33	-16	1.26	-20	-36	-40
Consolidated Net Income / (Loss)	-7.89	-6.57	-8.93	-12	-14	-33	-16	1.26	-21	-38	-40
Net Income / (Loss) Continuing Operations	-7.85	-6.57	-8.93	-12	-13	-33	-16	1.26	-20	-36	-40
Total Pre-Tax Income	-7.85	-6.57	-8.93	-12	-13	-34	-17	-3.69	-21	-42	-39
Total Operating Income	-6.59	-6.13	-6.47	-9.55	-9.08	-27	-18	-25	-27	-35	-39
Total Gross Profit	22	26	34	43	55	55	73	91	111	149	173
Total Revenue	31	37	46	58	73	71	98	122	149	205	236
Operating Revenue	31	37	46	58	73	71	98	122	149	205	236
Total Cost of Revenue	9.37	11	11	15	18	16	25	32	37	56	64
Operating Cost of Revenue	9.37	11	11	15	18	16	25	32	37	56	64
Total Operating Expenses	28	32	41	52	64	82	91	116	137	182	212
Selling, General & Admin Expense	11	12	17	21	27	38	46	58	73	103	120
Marketing Expense	15	17	21	27	31	32	40	46	53	64	73
Research & Development Expense	1.79	2.22	3.42	4.73	5.75	5.27	5.54	8.45	11	11	9.10
Impairment Charge	-	-	-	-	-	0.00	0.00	3.61	0.00	0.00	4.64
Restructuring Charge	-	-	-	-	-	-	-	0.00	0.00	3.65	5.60
Total Other Income / (Expense), net	-1.26	-0.45	-2.46	-2.47	-3.61	-6.91	0.64	22	5.44	-6.92	0.05
Interest Expense	1.23	1.48	2.49	2.26	3.54	3.41	2.25	2.42	-0.20	5.85	6.00
Other Income / (Expense), net	-0.03	1.03	0.03	-0.22	-0.07	0.02	2.88	24	5.24	-1.07	6.05
Income Tax Expense	-	-	-	0.00	0.00	-0.72	-1.13	-4.95	-0.34	-4.11	0.46
Basic Earnings per Share	($7.27)	($7.14)	($5.86)	($0.96)	($0.94)	($1.82)	($0.84)	$0.06	($0.92)	($1.64)	($1.69)
Weighted Average Basic Shares Outstanding	1.74M	1.74M	4.02M	12.57M	14.62M	18.06M	19.27M	20.70M	22.68M	23.08M	23.46M
Diluted Earnings per Share	($7.27)	($7.14)	($5.86)	($0.96)	($0.94)	($1.82)	($0.84)	$0.06	($0.92)	($1.64)	($1.69)
Weighted Average Diluted Shares Outstanding	1.74M	1.74M	4.02M	12.57M	14.62M	18.06M	19.27M	20.95M	22.68M	23.08M	23.46M
Weighted Average Basic & Diluted Shares Outstanding	1.74M	1.74M	4.02M	12.57M	14.62M	18.06M	39.49M	22.99M	23.55M	24.29M	25.28M

This table shows OrthoPediatrics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-4.59	-6.69	-7.81	-6.03	-7.92	-16	-11	-7.11	-12	-10	-11
Consolidated Net Income / (Loss)	-4.59	-6.69	-7.81	-6.03	-7.92	-16	-11	-7.11	-12	-10	-11
Net Income / (Loss) Continuing Operations	-4.59	-6.69	-7.81	-6.03	-7.92	-16	-11	-7.11	-12	-10	-11
Total Pre-Tax Income	-3.74	-6.90	-10	-6.05	-9.14	-16	-10	-7.06	-12	-9.76	-11
Total Operating Income	-4.51	-8.07	-9.72	-5.67	-5.57	-14	-11	-11	-9.43	-8.17	-8.34
Total Gross Profit	31	27	32	41	40	36	38	44	45	45	43
Total Revenue	40	38	45	53	55	53	52	61	61	62	59
Operating Revenue	40	38	45	53	55	53	52	61	61	62	59
Total Cost of Revenue	9.02	11	13	12	15	17	14	17	16	16	16
Operating Cost of Revenue	9.02	11	13	12	15	17	14	17	16	16	16
Total Operating Expenses	35	35	42	46	46	50	49	55	55	53	52
Selling, General & Admin Expense	18	19	25	27	26	24	30	30	29	30	31
Marketing Expense	14	13	14	17	17	17	17	19	19	18	18
Research & Development Expense	2.56	2.92	3.00	2.54	2.58	2.92	2.35	2.16	2.33	2.26	2.23
Restructuring Charge	-	-	0.00	0.00	0.00	-	0.04	2.97	2.29	0.30	0.00
Total Other Income / (Expense), net	0.77	1.16	-0.61	-0.38	-3.57	-2.35	0.52	3.59	-2.47	-1.59	-2.52
Interest Expense	0.02	-0.30	0.64	0.26	3.63	1.32	1.13	1.12	1.82	1.93	2.10
Other Income / (Expense), net	0.79	0.86	0.02	-0.12	0.06	-1.04	1.64	4.71	-0.65	0.34	-0.42
Income Tax Expense	0.85	-0.21	-2.53	-0.02	-1.22	-0.34	0.20	0.05	-0.13	0.34	-0.17
Basic Earnings per Share	($0.20)	($0.29)	($0.34)	($0.26)	($0.34)	($0.70)	($0.46)	($0.30)	($0.50)	($0.43)	($0.45)
Weighted Average Basic Shares Outstanding	22.76M	22.68M	22.82M	23.15M	23.17M	23.08M	23.23M	23.46M	23.57M	23.46M	23.69M
Diluted Earnings per Share	($0.20)	($0.29)	($0.34)	($0.26)	($0.34)	($0.70)	($0.46)	($0.30)	($0.50)	($0.43)	($0.45)
Weighted Average Diluted Shares Outstanding	22.76M	22.68M	22.82M	23.15M	23.17M	23.08M	23.23M	23.46M	23.57M	23.46M	23.69M
Weighted Average Basic & Diluted Shares Outstanding	23.35M	23.55M	23.83M	24.21M	24.22M	24.29M	24.77M	25.07M	25.08M	25.28M	25.68M

This table details how cash moves in and out of OrthoPediatrics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-2.70	-2.27	41	18	11	-42	-21	1.46	23	13	-24
Net Cash From Operating Activities	-0.89	-1.12	-7.22	-16	-18	-19	-13	-22	-27	-27	-4.85
Net Cash From Continuing Operating Activities	-0.89	-1.12	-7.22	-16	-18	-19	-13	-22	-27	-27	-4.85
Net Income / (Loss) Continuing Operations	-7.89	-6.57	-8.93	-12	-14	-33	-16	1.26	-21	-38	-40
Consolidated Net Income / (Loss)	-7.89	-6.57	-8.93	-12	-14	-33	-16	1.26	-21	-38	-40
Depreciation Expense	1.85	1.90	2.41	2.89	4.67	8.01	11	13	17	19	21
Non-Cash Adjustments To Reconcile Net Income	0.73	0.62	3.48	3.19	2.81	15	1.65	13	13	19	25
Changes in Operating Assets and Liabilities, net	4.42	2.93	-4.17	-9.64	-11	-8.53	-9.14	-49	-36	-28	-11
Net Cash From Investing Activities	-1.71	-4.75	-6.54	-5.97	-62	-70	-7.41	-113	42	-13	-44
Net Cash From Continuing Investing Activities	-1.71	-4.75	-6.54	-5.97	-62	-70	-7.41	-113	42	-13	-44
Purchase of Property, Plant & Equipment	-2.21	-4.35	-5.21	-5.25	-12	-11	-8.10	-10	-17	-14	-11
Acquisitions	-0.04	-0.41	-1.34	-0.21	-50	-4.19	-8.56	-40	-3.10	-23	-16
Purchase of Investments	-	-	-	0.00	0.00	-55	0.00	-110	-51	-26	-17
Sale and/or Maturity of Investments	-	-	-	-	0.00	0.00	9.25	47	113	50	0.00
Net Cash From Financing Activities	-0.10	3.60	55	40	91	47	0.01	136	7.30	53	24
Net Cash From Continuing Financing Activities	-0.10	3.60	55	40	91	47	0.01	136	7.30	53	24
Repayment of Debt	-0.10	-0.10	-0.08	-4.18	-0.12	-25	-0.13	-31	-0.14	-16	-0.16
Issuance of Debt	0.00	4.50	7.99	0.00	30	0.00	0.00	31	9.42	74	25
Other Financing Activities, net	0.00	0.00	-0.99	0.41	1.14	1.65	0.14	-3.17	-1.98	-4.61	-0.87
Effect of Exchange Rate Changes	-	-	-	-	0.01	-	-0.66	0.62	0.63	-0.18	0.35
Cash Interest Paid	1.23	1.48	2.49	2.26	4.23	1.23	0.06	0.70	0.04	2.75	6.52

This table details how cash moves in and out of OrthoPediatrics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	0.92	21	-9.46	7.33	22	-7.12	-10	11	-27	2.74	-7.69
Net Cash From Operating Activities	-8.67	-7.54	-6.69	-6.09	-10	-3.99	-4.16	-10	-0.58	10	-3.29
Net Cash From Continuing Operating Activities	-8.67	-7.54	-6.69	-6.09	-10	-3.99	-4.16	-10	-0.58	10	-3.29
Net Income / (Loss) Continuing Operations	-4.59	-6.69	-7.81	-6.03	-7.92	-16	-11	-7.11	-12	-10	-11
Consolidated Net Income / (Loss)	-4.59	-6.69	-7.81	-6.03	-7.92	-16	-11	-7.11	-12	-10	-11
Depreciation Expense	4.27	5.19	5.03	4.78	5.28	3.99	5.05	5.17	5.30	5.60	5.72
Non-Cash Adjustments To Reconcile Net Income	3.63	3.03	3.08	3.20	7.21	5.88	4.06	5.05	8.43	7.08	4.10
Changes in Operating Assets and Liabilities, net	-12	-9.07	-6.99	-8.04	-15	2.21	-2.61	-14	-2.54	7.77	-2.43
Net Cash From Investing Activities	9.67	18	-3.68	20	-27	-2.41	-5.99	-3.55	-27	-7.26	-3.79
Net Cash From Continuing Investing Activities	9.67	18	-3.68	20	-27	-2.41	-5.99	-3.55	-27	-7.26	-3.79
Purchase of Property, Plant & Equipment	-3.03	-3.84	-6.46	-6.68	-1.38	0.26	-4.23	-3.45	-2.84	-0.60	-1.76
Acquisitions	-4.00	49	-21	-	-25	23	-0.22	-0.10	-11	-4.64	-6.78
Purchase of Investments	-	-	0.00	-	-	-25	-1.54	-	-13	-2.02	-0.25
Sale and/or Maturity of Investments	17	24	23	26	-	-	0.00	-	-	-	5.00
Net Cash From Financing Activities	-0.02	9.39	-0.57	-4.27	59	-0.54	-0.13	25	-0.28	-0.42	-0.61
Net Cash From Continuing Financing Activities	-0.02	9.39	-0.57	-4.27	59	-0.54	-0.13	25	-0.28	-0.42	-0.61
Repayment of Debt	-0.04	-0.04	-0.04	-0.77	-15	0.57	-0.04	-0.04	-0.04	-0.04	-0.04
Other Financing Activities, net	0.02	-	-0.54	-	-	-1.11	-0.09	-0.16	-0.24	-0.38	-0.57
Cash Interest Paid	0.02	0.01	0.22	0.54	0.62	1.37	1.27	1.28	2.01	1.95	1.87

This table presents OrthoPediatrics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	31	82	112	182	320	304	428	439	473	509
Total Current Assets	21	70	97	128	158	134	227	226	237	256
Cash & Equivalents	1.61	43	61	71	29	-	8.99	31	44	20
Restricted Cash	-	-	0.00	1.25	1.37	1.37	1.47	1.97	1.96	2.06
Short-Term Investments	-	-	-	0.00	55	46	109	49	25	41
Accounts Receivable	4.10	5.60	9.00	16	17	18	25	35	42	54
Inventories, net	15	21	26	38	53	58	78	106	117	134
Prepaid Expenses	0.23	0.83	1.26	1.46	2.62	3.23	3.97	3.75	7.02	5.88
Plant, Property, & Equipment, net	8.59	10	13	21	27	29	34	41	51	50
Total Noncurrent Assets	1.26	2.35	2.18	33	135	142	167	171	185	203
Goodwill	-	-	0.00	14	71	72	87	84	94	109
Intangible Assets	1.26	2.35	2.18	19	64	70	80	85	81	78
Other Noncurrent Operating Assets	-	-	-	-	-	-	0.00	2.94	10	16
Total Liabilities & Shareholders' Equity	31	82	112	182	320	304	428	439	473	509
Total Liabilities	25	35	30	40	86	79	49	62	119	162
Total Current Liabilities	7.25	9.47	9.22	14	35	30	31	42	34	46
Short-Term Debt	0.11	0.11	0.12	0.12	0.13	0.14	0.14	0.15	0.16	0.17
Accounts Payable	3.54	5.50	3.97	6.47	10	9.33	11	13	8.91	19
Current Employee Benefit Liabilities	2.22	2.91	3.55	4.35	4.54	5.35	6.74	11	14	14
Other Current Liabilities	1.38	0.95	1.58	2.72	20	15	13	18	11	14
Total Noncurrent Liabilities	17	25	21	26	51	49	18	20	85	116
Long-Term Debt	17	25	21	26	1.04	0.91	0.76	9.91	73	100
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	0.00	5.76	4.77	5.95	5.48	3.38	3.58
Other Noncurrent Operating Liabilities	-	-	-	0.06	44	44	11	4.66	8.34	12
Total Equity & Noncontrolling Interests	-65	47	82	142	235	225	379	377	355	347
Total Preferred & Common Equity	-65	47	82	142	235	225	379	377	355	347
Total Common Equity	-65	47	82	142	235	225	379	377	355	347
Common Stock	13	150	197	271	389	395	561	580	601	622
Retained Earnings	-78	-103	-115	-129	-162	-178	-177	-198	-236	-275
Accumulated Other Comprehensive Income / (Loss)	0.00	0.14	-0.62	-0.00	7.91	8.49	-5.40	-5.53	-11	-0.52

This table presents OrthoPediatrics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	430	426	435	432	437	431	489	470	504	493	502
Total Current Assets	225	225	223	226	204	194	248	232	258	246	246
Cash & Equivalents	35	35	9.71	11	22	29	51	33	45	17	12
Restricted Cash	1.45	1.48	1.60	1.59	1.96	1.96	2.00	1.99	2.05	2.06	2.05
Short-Term Investments	85	73	83	72	26	0.00	25	25	26	41	37
Accounts Receivable	26	27	34	38	36	42	43	44	54	51	54
Inventories, net	74	85	91	101	113	116	121	120	125	129	134
Prepaid Expenses	2.75	4.01	3.64	3.98	5.06	4.50	6.49	7.55	6.44	5.99	6.55
Plant, Property, & Equipment, net	36	37	40	40	49	53	55	53	53	51	49
Total Noncurrent Assets	169	164	172	166	185	183	186	186	193	196	208
Goodwill	88	84	83	81	91	91	91	94	99	104	115
Intangible Assets	81	80	88	85	89	87	85	79	80	79	77
Other Noncurrent Operating Assets	-	-	0.61	0.62	4.08	6.47	10	13	14	14	16
Total Liabilities & Shareholders' Equity	430	426	435	432	437	431	489	470	504	493	502
Total Liabilities	47	53	55	58	67	59	118	123	148	144	163
Total Current Liabilities	29	35	44	48	46	40	35	38	39	33	47
Short-Term Debt	0.14	0.15	0.15	0.15	0.15	0.16	0.16	0.16	0.16	0.17	0.17
Accounts Payable	11	17	21	23	20	17	12	14	13	7.16	20
Current Employee Benefit Liabilities	6.32	6.24	8.16	8.67	9.77	13	13	11	13	14	13
Other Current Liabilities	11	12	15	17	16	9.80	9.60	12	12	12	15
Total Noncurrent Liabilities	18	18	10	10	21	20	84	86	109	111	116
Long-Term Debt	0.80	0.73	0.69	0.65	10	9.78	73	73	97	99	100
Noncurrent Deferred & Payable Income Tax Liabilities	5.46	6.02	5.56	5.49	5.20	4.74	4.03	3.39	3.53	3.80	3.36
Other Noncurrent Operating Liabilities	12	11	4.00	4.05	5.43	5.38	7.21	9.18	8.90	7.97	13
Total Equity & Noncontrolling Interests	383	373	380	374	371	371	371	347	356	349	339
Total Preferred & Common Equity	383	373	380	374	371	371	371	347	356	349	339
Total Common Equity	383	373	380	374	371	371	371	347	356	349	339
Common Stock	559	563	575	578	583	593	597	605	614	618	626
Retained Earnings	-169	-184	-186	-191	-206	-212	-219	-246	-253	-265	-286
Accumulated Other Comprehensive Income / (Loss)	-7.10	-6.05	-7.91	-12	-6.96	-10	-6.60	-12	-4.95	-3.63	-1.40

This table displays calculated financial ratios and metrics derived from OrthoPediatrics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	0.00	12,697,991.00	12,811,450.00	14,967,128.00	19,554,621.00	19,678,380.00	-	-	-	25,077,330.00
DEI Adjusted Shares Outstanding	0.00	0.00	12,697,991.00	12,811,450.00	14,967,128.00	19,554,621.00	19,678,380.00	-	-	-	25,077,330.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	0.00	-1.85	-0.94	-0.92	-1.68	-0.83	-	-	-	-1.58
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	20.30%	22.31%	26.17%	26.05%	-2.03%	37.95%	24.72%	21.62%	37.65%	15.45%
EBITDA Growth	0.00%	33.03%	-26.39%	-70.37%	34.92%	-318.34%	76.18%	365.28%	-134.86%	-312.07%	28.97%
EBIT Growth	0.00%	23.06%	-26.41%	-51.66%	6.38%	-192.28%	43.37%	91.65%	-1,600.40%	-67.73%	8.00%
NOPAT Growth	0.00%	7.05%	-5.63%	-47.61%	4.98%	-194.76%	32.63%	-40.92%	-5.32%	-30.87%	-12.08%
Net Income Growth	0.00%	16.72%	-35.91%	-34.63%	-14.19%	-139.92%	50.64%	107.74%	-1,767.25%	-80.33%	-4.83%
EPS Growth	0.00%	1.79%	17.93%	83.62%	2.08%	-93.62%	53.85%	107.14%	-1,633.33%	-78.26%	-3.05%
Operating Cash Flow Growth	0.00%	-25.45%	-544.95%	-115.92%	-14.03%	-4.28%	29.50%	-66.62%	-24.26%	-0.01%	82.07%
Free Cash Flow Firm Growth	0.00%	0.00%	50.51%	-43.67%	-224.96%	-20.33%	54.10%	-217.08%	39.91%	-20.17%	29.18%
Invested Capital Growth	0.00%	0.00%	38.51%	39.35%	128.11%	56.09%	13.83%	51.48%	17.33%	17.09%	7.50%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	5.28%	6.43%	-0.04%	6.39%	5.32%	4.66%	7.94%	3.93%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	25.33%	-9.54%	-41.97%	62.60%	-38.24%	54.74%	-114.62%	42.35%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	18.89%	-13.50%	-31.71%	31.52%	-118.68%	13.38%	-27.96%	17.95%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	19.65%	-14.72%	-56.99%	28.49%	65.44%	0.90%	-20.64%	13.04%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	16.50%	-27.49%	-35.24%	46.42%	-86.29%	5.23%	-32.97%	13.08%
EPS Q/Q Growth	0.00%	0.00%	0.00%	47.25%	-23.68%	-25.52%	46.84%	-84.21%	3.16%	-33.33%	13.78%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-180.05%	3.68%	-30.93%	26.76%	-8.99%	-10.71%	-18.39%	11.62%	74.72%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-40.41%	33.91%	-11.93%	29.75%	-34.69%	19.14%	1.23%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	182.67%	83.63%	-0.15%	5.12%	-1.10%	4.70%	-2.36%	-1.34%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	69.79%	70.69%	75.52%	74.15%	75.28%	77.42%	74.86%	74.14%	74.80%	72.58%	73.05%
EBITDA Margin	-15.38%	-8.56%	-8.85%	-11.95%	-6.17%	-26.34%	-4.55%	9.68%	-2.77%	-8.30%	-5.11%
Operating Margin	-21.26%	-16.43%	-14.19%	-16.60%	-12.51%	-37.64%	-18.38%	-20.77%	-17.99%	-17.10%	-16.60%
EBIT Margin	-21.36%	-13.66%	-14.12%	-16.97%	-12.61%	-37.61%	-15.44%	-1.03%	-14.46%	-17.62%	-14.04%
Profit (Net Income) Margin	-25.45%	-17.62%	-19.58%	-20.89%	-18.93%	-46.35%	-16.58%	1.03%	-14.10%	-18.47%	-16.78%
Tax Burden Percent	100.48%	100.00%	100.00%	100.00%	108.25%	97.85%	93.51%	-34.10%	98.41%	90.20%	101.17%
Interest Burden Percent	118.57%	128.96%	138.65%	123.08%	138.68%	125.93%	114.84%	291.62%	99.08%	116.22%	118.06%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-39.13%	-17.33%	-18.40%	-9.15%	-15.15%	-7.83%	-8.24%	-6.63%	-7.41%	-7.42%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-67.79%	715.66%	0.48%	8.15%	6.73%	-2.55%	-30.29%	-4.28%	30.69%	-69.25%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-180.16%	-16.07%	-0.21%	-3.10%	-2.32%	0.76%	8.66%	1.08%	-2.93%	-3.89%
Return on Equity (ROE)	0.00%	-219.29%	-33.40%	-18.61%	-12.25%	-17.47%	-7.07%	0.42%	-5.55%	-10.34%	-11.31%
Cash Return on Invested Capital (CROIC)	0.00%	-239.13%	-49.62%	-51.29%	-87.24%	-58.96%	-20.77%	-49.19%	-22.58%	-23.15%	-14.65%
Operating Return on Assets (OROA)	0.00%	-16.61%	-11.40%	-10.05%	-6.22%	-10.64%	-4.85%	-0.35%	-4.97%	-7.91%	-6.76%
Return on Assets (ROA)	0.00%	-21.42%	-15.81%	-12.37%	-9.33%	-13.11%	-5.21%	0.34%	-4.84%	-8.29%	-8.08%
Return on Common Equity (ROCE)	0.00%	2,389.28%	11.12%	-18.61%	-12.25%	-17.47%	-7.07%	0.42%	-5.55%	-10.34%	-11.31%
Return on Equity Simple (ROE_SIMPLE)	0.00%	10.06%	-18.81%	-14.71%	-9.65%	-14.03%	-7.21%	0.33%	-5.56%	-10.67%	0.00%
Net Operating Profit after Tax (NOPAT)	-4.61	-4.29	-4.53	-6.69	-6.35	-19	-13	-18	-19	-25	-27
NOPAT Margin	-14.88%	-11.50%	-9.93%	-11.62%	-8.76%	-26.35%	-12.87%	-14.54%	-12.59%	-11.97%	-11.62%
Net Nonoperating Expense Percent (NNEP)	0.00%	28.67%	-732.99%	-18.88%	-17.31%	-21.88%	-5.28%	22.04%	-2.35%	-38.10%	61.83%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-4.68%	-4.84%	-5.73%	-6.15%
Cost of Revenue to Revenue	30.21%	29.31%	24.48%	25.85%	24.72%	22.58%	25.14%	25.86%	25.20%	27.42%	26.95%
SG&A Expenses to Revenue	36.79%	31.18%	37.20%	36.38%	36.75%	53.91%	46.98%	47.35%	49.28%	50.21%	50.70%
R&D to Revenue	5.77%	5.96%	7.50%	8.22%	7.92%	7.42%	5.65%	6.91%	7.33%	5.39%	3.85%
Operating Expenses to Revenue	91.05%	87.12%	89.70%	90.75%	87.79%	115.07%	93.25%	94.91%	92.79%	89.68%	89.66%
Earnings before Interest and Taxes (EBIT)	-6.62	-5.10	-6.44	-9.77	-9.15	-27	-15	-1.27	-22	-36	-33
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-4.77	-3.19	-4.04	-6.88	-4.48	-19	-4.46	12	-4.13	-17	-12
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	5.13	5.47	4.94	3.44	5.23	2.40	2.01	1.58	1.29
Price to Tangible Book Value (P/TBV)	0.00	0.00	5.40	5.62	6.42	8.07	14.15	4.29	3.64	3.13	2.79
Price to Revenue (P/Rev)	0.00	0.00	5.34	7.76	9.69	11.35	12.01	7.44	5.10	2.74	1.88
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	722.96	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.14%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	7.46	9.63	6.81	4.80	6.60	3.04	2.25	1.58	1.26
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	4.97	7.08	9.06	10.17	11.54	6.47	4.62	2.75	2.04
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	66.81	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	2.93	0.54	0.26	0.18	0.01	0.00	0.00	0.03	0.21	0.29
Long-Term Debt to Equity	0.00	2.91	0.53	0.26	0.18	0.00	0.00	0.00	0.03	0.21	0.29
Financial Leverage	0.00	2.66	-0.02	-0.44	-0.38	-0.34	-0.30	-0.29	-0.25	-0.10	0.06
Leverage Ratio	0.00	5.12	2.11	1.50	1.31	1.33	1.36	1.21	1.15	1.25	1.40
Compound Leverage Factor	0.00	6.60	2.93	1.85	1.82	1.68	1.56	3.53	1.14	1.45	1.65
Debt to Total Capital	0.00%	74.53%	34.89%	20.65%	15.54%	0.50%	0.46%	0.24%	2.60%	17.10%	22.39%
Short-Term Debt to Total Capital	0.00%	0.45%	0.15%	0.11%	0.07%	0.06%	0.06%	0.04%	0.04%	0.04%	0.04%
Long-Term Debt to Total Capital	0.00%	74.07%	34.74%	20.54%	15.47%	0.44%	0.40%	0.20%	2.56%	17.06%	22.35%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	303.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-277.53%	65.11%	79.35%	84.46%	99.50%	99.54%	99.76%	97.40%	82.90%	77.61%
Debt to EBITDA	0.00	-5.49	-6.30	-3.09	-5.85	-0.06	-0.23	0.08	-2.44	-4.30	-8.28
Net Debt to EBITDA	0.00	-4.99	4.24	5.73	10.24	4.49	10.36	-10.04	17.51	-0.14	-3.07
Long-Term Debt to EBITDA	0.00	-5.46	-6.28	-3.08	-5.82	-0.06	-0.20	0.06	-2.40	-4.29	-8.27
Debt to NOPAT	0.00	-4.09	-5.62	-3.18	-4.12	-0.06	-0.08	-0.05	-0.54	-2.98	-3.64
Net Debt to NOPAT	0.00	-3.71	3.78	5.89	7.21	4.49	3.66	6.69	3.86	-0.09	-1.35
Long-Term Debt to NOPAT	0.00	-4.06	-5.59	-3.16	-4.10	-0.06	-0.07	-0.04	-0.53	-2.98	-3.63
Altman Z-Score	0.00	0.00	3.62	8.56	10.60	5.35	8.71	11.37	7.43	2.84	1.64
Noncontrolling Interest Sharing Ratio	0.00%	1,189.57%	133.30%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	2.87	7.35	10.54	9.37	4.52	4.50	7.34	5.44	6.98	5.55
Quick Ratio	0.00	0.79	5.09	7.62	6.39	2.90	2.15	4.64	2.76	3.27	2.48
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-26	-13	-19	-61	-73	-33	-106	-64	-77	-54
Operating Cash Flow to CapEx	-53.35%	-25.74%	-138.60%	-296.65%	-150.38%	-176.41%	-161.21%	-216.99%	-155.22%	-189.64%	-43.66%
Free Cash Flow to Firm to Interest Expense	0.00	-17.76	-5.21	-8.26	-17.12	-21.36	-14.89	-43.76	0.00	-13.09	-9.05
Operating Cash Flow to Interest Expense	-0.73	-0.76	-2.90	-6.91	-5.02	-5.43	-5.81	-8.98	0.00	-4.62	-0.81
Operating Cash Flow Less CapEx to Interest Expense	-2.08	-3.70	-4.99	-9.24	-8.36	-8.51	-9.42	-13.12	0.00	-7.06	-2.66
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	1.22	0.81	0.59	0.49	0.28	0.31	0.33	0.34	0.45	0.48
Accounts Receivable Turnover	0.00	9.10	9.41	7.88	5.80	4.28	5.58	5.72	5.01	5.32	4.91
Inventory Turnover	0.00	0.73	0.63	0.64	0.56	0.35	0.45	0.47	0.41	0.50	0.51
Fixed Asset Turnover	0.00	4.34	4.81	4.97	4.25	2.93	3.52	3.89	3.95	4.47	4.72
Accounts Payable Turnover	0.00	3.09	2.47	3.14	3.44	1.94	2.55	3.09	3.15	5.21	4.60
Days Sales Outstanding (DSO)	0.00	40.10	38.81	46.30	62.89	85.28	65.43	63.79	72.91	68.62	74.28
Days Inventory Outstanding (DIO)	0.00	497.06	578.89	567.32	648.34	1,034.80	818.67	783.34	896.18	724.60	718.67
Days Payable Outstanding (DPO)	0.00	118.31	147.67	116.11	106.23	187.71	143.38	118.14	115.89	70.09	79.36
Cash Conversion Cycle (CCC)	0.00	418.86	470.03	497.51	605.01	932.38	740.72	728.99	853.20	723.13	713.59
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	22	30	42	97	151	172	260	305	357	384
Invested Capital Turnover	0.00	3.40	1.75	1.58	1.05	0.58	0.61	0.57	0.53	0.62	0.64
Increase / (Decrease) in Invested Capital	0.00	22	8.44	12	54	54	21	88	45	52	27
Enterprise Value (EV)	0.00	0.00	227	407	657	723	1,132	791	687	564	482
Market Capitalization	0.00	0.00	244	447	703	807	1,178	909	759	561	445
Book Value per Share	$0.00	($37.44)	$3.74	$6.38	$9.51	$12.01	$11.45	$16.54	$16.14	$14.64	$13.82
Tangible Book Value per Share	$0.00	($38.16)	$3.56	$6.21	$7.32	$5.11	$4.23	$9.26	$8.94	$7.41	$6.37
Total Capital	0.00	24	73	103	169	236	226	380	387	428	447
Total Debt	0.00	18	25	21	26	1.18	1.04	0.91	10	73	100
Total Long-Term Debt	0.00	17	25	21	26	1.04	0.91	0.76	9.91	73	100
Net Debt	0.00	16	-17	-39	-46	-84	-46	-119	-72	2.33	37
Capital Expenditures (CapEx)	1.67	4.35	5.21	5.25	12	11	8.10	10	17	14	11
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	12	18	27	42	38	57	76	103	133	147
Debt-free Net Working Capital (DFNWC)	0.00	14	60	88	115	124	104	196	185	203	210
Net Working Capital (NWC)	0.00	14	60	88	114	123	104	196	185	203	210
Net Nonoperating Expense (NNE)	3.28	2.28	4.40	5.34	7.38	14	3.64	-19	2.25	13	12
Net Nonoperating Obligations (NNO)	0.00	16	-17	-39	-46	-84	-54	-119	-72	2.33	37
Total Depreciation and Amortization (D&A)	1.85	1.90	2.41	2.89	4.67	8.01	11	13	17	19	21
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	32.37%	38.63%	47.54%	58.57%	53.83%	57.93%	62.34%	69.05%	64.76%	62.40%
Debt-free Net Working Capital to Revenue	0.00%	36.68%	131.98%	152.99%	157.84%	173.80%	106.14%	160.27%	124.37%	99.34%	89.02%
Net Working Capital to Revenue	0.00%	36.40%	131.73%	152.78%	157.67%	173.61%	106.00%	160.15%	124.27%	99.26%	88.95%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($7.27)	($7.14)	($5.86)	($0.96)	($0.94)	($1.82)	($0.84)	$0.06	($0.92)	($1.64)	($1.69)
Adjusted Weighted Average Basic Shares Outstanding	1.74M	1.74M	12.77M	14.54M	16.88M	19.66M	19.27M	20.70M	22.68M	23.08M	23.46M
Adjusted Diluted Earnings per Share	($7.27)	($7.14)	($5.86)	($0.96)	($0.94)	($1.82)	($0.84)	$0.06	($0.92)	($1.64)	($1.69)
Adjusted Weighted Average Diluted Shares Outstanding	1.74M	1.74M	12.77M	14.54M	16.88M	19.66M	19.27M	20.95M	22.68M	23.08M	23.46M
Adjusted Basic & Diluted Earnings per Share	($7.27)	($7.14)	($5.86)	($0.96)	($0.94)	($1.82)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.74M	1.74M	4.02M	12.57M	14.62M	18.06M	39.49M	22.99M	23.55M	24.29M	25.28M
Normalized Net Operating Profit after Tax (NOPAT)	-4.61	-4.29	-4.53	-6.69	-6.35	-12	-13	-15	-18	-21	-20
Normalized NOPAT Margin	-14.88%	-11.50%	-9.93%	-11.62%	-8.76%	-16.64%	-12.76%	-12.47%	-12.13%	-10.09%	-8.59%
Pre Tax Income Margin	-25.33%	-17.62%	-19.58%	-20.89%	-17.48%	-47.37%	-17.73%	-3.02%	-14.33%	-20.48%	-16.58%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-5.38	-3.45	-2.59	-4.33	-2.59	-7.84	-6.74	-0.52	0.00	-6.17	-5.54
NOPAT to Interest Expense	-3.75	-2.91	-1.82	-2.97	-1.80	-5.49	-5.62	-7.33	0.00	-4.19	-4.58
EBIT Less CapEx to Interest Expense	-6.74	-6.40	-4.68	-6.66	-5.93	-10.91	-10.34	-4.66	0.00	-8.60	-7.39
NOPAT Less CapEx to Interest Expense	-5.11	-5.85	-3.91	-5.29	-5.14	-8.57	-9.22	-11.47	0.00	-6.63	-6.43
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	-66.78%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-12.08%	-66.78%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from OrthoPediatrics' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	24,286,590.00	24,769,049.00	25,073,602.00	25,077,330.00	25,278,787.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	24,286,590.00	24,769,049.00	25,073,602.00	25,077,330.00	25,278,787.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-0.44	-0.29	-0.47	-0.40	-0.42
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	14.37%	21.36%	41.46%	33.48%	36.53%	40.02%	17.29%	15.68%	12.24%	16.97%	13.26%
EBITDA Growth	-97.01%	71.19%	-24.83%	-192.64%	-140.62%	-449.63%	8.18%	22.74%	-2,042.15%	79.91%	29.24%
EBIT Growth	-124.64%	31.55%	-27.79%	-93.32%	-47.89%	-109.41%	3.73%	-2.80%	-83.10%	48.10%	6.22%
NOPAT Growth	64.80%	2.92%	-13.18%	-1.43%	-23.47%	-74.25%	-12.94%	-88.09%	-69.39%	41.86%	24.10%
Net Income Growth	-124.76%	14.74%	-14.68%	-108.91%	-72.49%	-140.16%	-36.57%	-17.98%	-48.67%	37.13%	-0.26%
EPS Growth	-122.99%	9.38%	-13.33%	-100.00%	-70.00%	-141.38%	-35.29%	-15.38%	-47.06%	38.57%	2.17%
Operating Cash Flow Growth	-43.10%	-125.77%	-3.54%	-39.31%	-18.57%	47.14%	37.88%	-71.73%	94.35%	359.54%	20.91%
Free Cash Flow Firm Growth	70.89%	46.17%	27.67%	18.73%	-147.95%	-22.24%	50.70%	44.66%	61.77%	47.52%	3.89%
Invested Capital Growth	10.82%	17.33%	25.06%	22.34%	25.56%	17.09%	8.57%	8.60%	6.38%	7.50%	8.02%
Revenue Q/Q Growth	1.04%	-5.90%	18.80%	18.16%	3.35%	-3.49%	-0.49%	16.54%	0.28%	0.58%	-3.64%
EBITDA Q/Q Growth	-49.49%	-467.76%	-131.35%	78.44%	77.86%	-4,876.23%	61.35%	81.86%	-514.01%	53.34%	-36.16%
EBIT Q/Q Growth	-24.32%	-93.66%	-34.60%	40.34%	4.89%	-174.21%	38.12%	36.30%	-69.40%	22.28%	-11.81%
NOPAT Q/Q Growth	19.30%	-78.93%	-20.54%	41.73%	1.76%	-152.52%	21.87%	2.95%	11.53%	13.32%	-1.99%
Net Income Q/Q Growth	-59.08%	-45.74%	-16.65%	22.75%	-31.35%	-102.92%	33.67%	33.27%	-65.51%	14.19%	-5.78%
EPS Q/Q Growth	-53.85%	-45.00%	-17.24%	23.53%	-30.77%	-105.88%	34.29%	34.78%	-66.67%	14.00%	-4.65%
Operating Cash Flow Q/Q Growth	-98.24%	12.99%	11.31%	8.94%	-68.73%	61.21%	-4.24%	-151.73%	94.45%	1,881.07%	-131.76%
Free Cash Flow Firm Q/Q Growth	62.22%	-60.40%	-44.45%	7.15%	-15.26%	20.92%	41.74%	-4.23%	20.39%	-8.57%	-6.69%
Invested Capital Q/Q Growth	1.66%	4.70%	8.65%	5.78%	4.34%	-2.36%	0.75%	5.82%	2.20%	-1.34%	1.24%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	77.44%	71.02%	72.00%	77.27%	73.41%	67.53%	73.00%	72.07%	73.92%	73.22%	73.09%
EBITDA Margin	1.37%	-5.37%	-10.45%	-1.91%	-0.41%	-21.07%	-8.18%	-1.27%	-7.80%	-3.62%	-5.11%
Operating Margin	-11.28%	-21.44%	-21.76%	-10.73%	-10.20%	-26.69%	-20.95%	-17.45%	-15.39%	-13.27%	-14.04%
EBIT Margin	-9.31%	-19.16%	-21.71%	-10.96%	-10.08%	-28.65%	-17.82%	-9.74%	-16.45%	-12.71%	-14.75%
Profit (Net Income) Margin	-11.49%	-17.79%	-17.47%	-11.42%	-14.51%	-30.51%	-20.34%	-11.65%	-19.22%	-16.40%	-18.00%
Tax Burden Percent	122.69%	96.93%	75.51%	99.70%	86.67%	97.93%	101.87%	100.69%	98.95%	103.48%	98.43%
Interest Burden Percent	100.56%	95.80%	106.57%	104.51%	166.04%	108.74%	112.06%	118.76%	118.08%	124.67%	124.01%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-4.05%	-7.91%	-8.27%	-4.13%	-4.12%	-11.56%	-9.02%	-7.38%	-6.50%	-5.93%	-6.39%
ROIC Less NNEP Spread (ROIC-NNEP)	-2.64%	-6.82%	-6.92%	-0.54%	4.96%	6.27%	13.02%	9.90%	-36.78%	-28.17%	-22.02%
Return on Net Nonoperating Assets (RNNOA)	0.71%	1.72%	1.37%	0.08%	-0.59%	-0.60%	-0.49%	0.05%	-1.74%	-1.58%	-1.99%
Return on Equity (ROE)	-3.34%	-6.19%	-6.90%	-4.05%	-4.71%	-12.16%	-9.51%	-7.32%	-8.24%	-7.51%	-8.39%
Cash Return on Invested Capital (CROIC)	-17.09%	-22.58%	-28.82%	-26.24%	-28.85%	-23.15%	-15.57%	-16.15%	-14.56%	-14.65%	-14.56%
Operating Return on Assets (OROA)	-3.07%	-6.58%	-8.14%	-4.43%	-4.15%	-12.86%	-8.34%	-4.60%	-7.61%	-6.12%	-7.38%
Return on Assets (ROA)	-3.78%	-6.11%	-6.55%	-4.62%	-5.97%	-13.70%	-9.52%	-5.50%	-8.90%	-7.90%	-9.01%
Return on Common Equity (ROCE)	-3.34%	-6.19%	-6.90%	-4.05%	-4.71%	-12.16%	-9.51%	-7.32%	-8.24%	-7.51%	-8.39%
Return on Equity Simple (ROE_SIMPLE)	-5.91%	0.00%	-5.93%	-6.76%	-7.67%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-3.16	-5.65	-6.81	-3.97	-3.90	-9.84	-7.69	-7.46	-6.60	-5.72	-5.83
NOPAT Margin	-7.89%	-15.01%	-15.23%	-7.51%	-7.14%	-18.68%	-14.67%	-12.21%	-10.77%	-9.29%	-9.83%
Net Nonoperating Expense Percent (NNEP)	-1.41%	-1.09%	-1.35%	-3.59%	-9.08%	-17.83%	-22.04%	-17.28%	30.29%	22.25%	15.62%
Return On Investment Capital (ROIC_SIMPLE)	-	-1.46%	-	-	-	-2.30%	-1.83%	-1.65%	-1.47%	-1.28%	-1.33%
Cost of Revenue to Revenue	22.56%	28.98%	28.00%	22.73%	26.59%	32.47%	27.00%	27.93%	26.08%	26.78%	26.91%
SG&A Expenses to Revenue	44.96%	50.67%	55.34%	51.76%	48.19%	46.39%	57.77%	49.84%	47.60%	48.62%	52.26%
R&D to Revenue	6.41%	7.77%	6.71%	4.82%	4.72%	5.54%	4.49%	3.53%	3.81%	3.67%	3.76%
Operating Expenses to Revenue	88.71%	92.47%	93.76%	88.00%	83.61%	94.21%	93.96%	89.51%	89.31%	86.48%	87.13%
Earnings before Interest and Taxes (EBIT)	-3.72	-7.21	-9.70	-5.79	-5.50	-15	-9.34	-5.95	-10	-7.83	-8.76
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	0.55	-2.02	-4.67	-1.01	-0.22	-11	-4.29	-0.78	-4.78	-2.23	-3.04
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.00	2.01	1.85	1.85	1.77	1.58	1.72	1.50	1.33	1.29	1.18
Price to Tangible Book Value (P/TBV)	3.58	3.64	3.62	3.53	3.37	3.13	3.43	3.02	2.79	2.79	2.73
Price to Revenue (P/Rev)	5.26	5.10	4.24	3.91	3.46	2.74	2.82	2.41	2.04	1.88	1.65
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.28	2.25	1.95	1.90	1.78	1.58	1.70	1.46	1.30	1.26	1.16
Enterprise Value to Revenue (EV/Rev)	4.67	4.62	4.00	3.79	3.43	2.75	2.87	2.52	2.22	2.04	1.85
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.03	0.03	0.03	0.20	0.21	0.21	0.27	0.28	0.29	0.30
Long-Term Debt to Equity	0.00	0.03	0.03	0.03	0.20	0.21	0.21	0.27	0.28	0.29	0.30
Financial Leverage	-0.27	-0.25	-0.20	-0.15	-0.12	-0.10	-0.04	0.01	0.05	0.06	0.09
Leverage Ratio	1.14	1.15	1.16	1.15	1.24	1.25	1.26	1.29	1.36	1.40	1.42
Compound Leverage Factor	1.14	1.10	1.24	1.20	2.05	1.36	1.42	1.53	1.61	1.75	1.76
Debt to Total Capital	0.21%	2.60%	2.71%	2.61%	16.38%	17.10%	17.41%	21.47%	22.14%	22.39%	22.89%
Short-Term Debt to Total Capital	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%
Long-Term Debt to Total Capital	0.17%	2.56%	2.67%	2.57%	16.35%	17.06%	17.37%	21.43%	22.11%	22.35%	22.85%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.79%	97.40%	97.29%	97.39%	83.62%	82.90%	82.59%	78.54%	77.86%	77.61%	77.11%
Debt to EBITDA	-0.09	-2.44	-2.04	-1.39	-9.18	-4.30	-4.40	-5.93	-4.74	-8.28	-9.29
Net Debt to EBITDA	9.13	17.51	7.80	2.93	0.68	-0.14	-0.75	-1.52	-1.89	-3.07	-4.59
Long-Term Debt to EBITDA	-0.07	-2.40	-2.01	-1.37	-9.16	-4.29	-4.39	-5.92	-4.74	-8.27	-9.28
Debt to NOPAT	-0.04	-0.54	-0.53	-0.51	-3.58	-2.98	-2.88	-3.36	-3.15	-3.64	-3.93
Net Debt to NOPAT	4.40	3.86	2.02	1.07	0.27	-0.09	-0.49	-0.86	-1.25	-1.35	-1.94
Long-Term Debt to NOPAT	-0.03	-0.53	-0.52	-0.50	-3.57	-2.98	-2.88	-3.36	-3.14	-3.63	-3.92
Altman Z-Score	7.89	7.54	6.26	7.02	3.57	2.98	3.07	2.37	2.09	1.80	1.58
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.72	5.44	4.45	4.90	7.17	6.98	6.19	6.66	7.40	5.55	5.21
Quick Ratio	2.51	2.76	1.83	1.79	3.43	3.27	2.74	3.21	3.28	2.48	2.19
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-32	-51	-73	-68	-78	-62	-36	-38	-30	-32	-35
Operating Cash Flow to CapEx	-286.58%	-196.64%	-103.56%	-91.14%	-744.32%	0.00%	-98.32%	-303.69%	-20.47%	1,727.55%	-186.76%
Free Cash Flow to Firm to Interest Expense	-1,503.93	0.00	-114.87	-260.31	-21.55	-46.95	-32.04	-33.69	-16.43	-16.82	-16.50
Operating Cash Flow to Interest Expense	-412.81	0.00	-10.50	-23.34	-2.83	-3.02	-3.69	-9.37	-0.32	5.36	-1.56
Operating Cash Flow Less CapEx to Interest Expense	-556.86	0.00	-20.64	-48.95	-3.21	-2.82	-7.44	-12.46	-1.88	5.05	-2.40
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.33	0.34	0.37	0.40	0.41	0.45	0.47	0.47	0.46	0.48	0.50
Accounts Receivable Turnover	4.45	5.01	5.13	4.61	4.71	5.32	5.29	4.61	4.83	4.91	4.94
Inventory Turnover	0.42	0.41	0.42	0.43	0.45	0.50	0.50	0.52	0.51	0.51	0.52
Fixed Asset Turnover	3.71	3.95	3.78	3.74	3.99	4.47	4.19	4.15	4.29	4.72	4.81
Accounts Payable Turnover	2.17	3.15	2.30	2.35	2.92	5.21	3.40	4.23	6.84	4.60	3.86
Days Sales Outstanding (DSO)	81.97	72.91	71.17	79.10	77.43	68.62	68.95	79.23	75.52	74.28	73.83
Days Inventory Outstanding (DIO)	876.47	896.18	859.42	851.67	809.55	724.60	734.34	701.89	708.94	718.67	706.97
Days Payable Outstanding (DPO)	168.03	115.89	158.43	155.64	125.14	70.09	107.21	86.24	53.40	79.36	94.44
Cash Conversion Cycle (CCC)	790.41	853.20	772.17	775.12	761.84	723.13	696.08	694.88	731.06	713.59	686.36
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	291	305	331	350	366	357	360	380	389	384	388
Invested Capital Turnover	0.51	0.53	0.54	0.55	0.58	0.62	0.62	0.60	0.60	0.64	0.65
Increase / (Decrease) in Invested Capital	28	45	66	64	74	52	28	30	23	27	29
Enterprise Value (EV)	664	687	647	664	651	564	611	557	504	482	451
Market Capitalization	747	759	687	685	656	561	598	532	465	445	401
Book Value per Share	$16.03	$16.14	$15.74	$15.58	$15.32	$14.64	$14.29	$14.35	$13.93	$13.82	$13.40
Tangible Book Value per Share	$8.95	$8.94	$8.07	$8.15	$8.05	$7.41	$7.18	$7.12	$6.64	$6.37	$5.81
Total Capital	375	387	381	381	444	428	420	453	449	447	439
Total Debt	0.80	10	10	9.94	73	73	73	97	99	100	101
Total Long-Term Debt	0.65	9.91	10	9.78	73	73	73	97	99	100	100
Net Debt	-83	-72	-39	-21	-5.39	2.33	12	25	40	37	50
Capital Expenditures (CapEx)	3.03	3.84	6.46	6.68	1.38	-0.26	4.23	3.45	2.84	0.60	1.76
Debt-free, Cash-free Net Working Capital (DFCFNWC)	94	103	108	123	136	133	134	147	153	147	148
Debt-free Net Working Capital (DFNWC)	178	185	158	154	214	203	195	219	213	210	199
Net Working Capital (NWC)	178	185	158	154	214	203	195	219	213	210	199
Net Nonoperating Expense (NNE)	1.44	1.04	1.00	2.06	4.02	6.23	2.97	-0.35	5.17	4.38	4.85
Net Nonoperating Obligations (NNO)	-83	-72	-39	-21	-5.39	2.33	12	25	40	37	50
Total Depreciation and Amortization (D&A)	4.27	5.19	5.03	4.78	5.28	3.99	5.05	5.17	5.30	5.60	5.72
Debt-free, Cash-free Net Working Capital to Revenue	66.41%	69.05%	66.96%	70.53%	71.59%	64.76%	63.05%	66.60%	67.28%	62.40%	60.83%
Debt-free Net Working Capital to Revenue	125.53%	124.37%	97.67%	88.18%	112.74%	99.34%	91.65%	99.31%	93.57%	89.02%	81.73%
Net Working Capital to Revenue	125.42%	124.27%	97.58%	88.09%	112.66%	99.26%	91.58%	99.23%	93.50%	88.95%	81.66%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.20)	($0.29)	($0.34)	($0.26)	($0.34)	($0.70)	($0.46)	($0.30)	($0.50)	($0.43)	($0.45)
Adjusted Weighted Average Basic Shares Outstanding	22.76M	22.68M	22.82M	23.15M	23.17M	23.08M	23.23M	23.46M	23.57M	23.46M	23.69M
Adjusted Diluted Earnings per Share	($0.20)	($0.29)	($0.34)	($0.26)	($0.34)	($0.70)	($0.46)	($0.30)	($0.50)	($0.43)	($0.45)
Adjusted Weighted Average Diluted Shares Outstanding	22.76M	22.68M	22.82M	23.15M	23.17M	23.08M	23.23M	23.46M	23.57M	23.46M	23.69M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	23.35M	23.55M	23.83M	24.21M	24.22M	24.29M	24.77M	25.07M	25.08M	25.28M	25.68M
Normalized Net Operating Profit after Tax (NOPAT)	-2.47	-5.65	-6.81	-3.97	-3.90	-9.84	-7.66	-5.38	-3.41	-5.51	-5.83
Normalized NOPAT Margin	-6.17%	-15.01%	-15.23%	-7.51%	-7.14%	-18.68%	-14.61%	-8.81%	-5.56%	-8.95%	-9.83%
Pre Tax Income Margin	-9.36%	-18.35%	-23.13%	-11.45%	-16.74%	-31.16%	-19.96%	-11.56%	-19.43%	-15.85%	-18.29%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-177.19	0.00	-15.23	-22.17	-1.51	-11.44	-8.29	-5.33	-5.53	-4.05	-4.17
NOPAT to Interest Expense	-150.27	0.00	-10.68	-15.20	-1.07	-7.46	-6.83	-6.68	-3.62	-2.96	-2.78
EBIT Less CapEx to Interest Expense	-321.24	0.00	-25.37	-47.78	-1.89	-11.24	-12.05	-8.42	-7.09	-4.36	-5.00
NOPAT Less CapEx to Interest Expense	-294.31	0.00	-20.83	-40.81	-1.45	-7.26	-10.58	-9.77	-5.18	-3.27	-3.61
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

OrthoPediatrics (NASDAQ: KIDS) showed continued revenue growth in Q1 2026, but profitability and cash generation remained under pressure. The company is still expanding sales, yet it is also spending heavily on marketing, SG&A, and acquisitions, which kept it in a net loss and negative operating cash flow position.

What stands out most is that revenue has improved meaningfully over the last few years, but expenses have grown too, and recent quarters show operating losses persisting despite the larger top line. The balance sheet still looks reasonably liquid, but cash declined sharply during Q1 2026 after a very strong year-end 2025 cash position.

Q1 2026 revenue rose to $59.4 million, up from $52.4 million in Q1 2025, showing continued top-line growth.
Gross profit increased to $43.4 million in Q1 2026, with gross margin holding near the low-70% range.
Total current assets were $245.9 million in Q1 2026, supported by cash, investments, inventory, and receivables.
The company still has a sizable equity base, with $338.7 million in total common equity as of Q1 2026.
Inventory growth alongside revenue growth suggests the company is building product availability to support demand.
Q1 2026 short-term investments of $36.6 million provided an additional liquidity cushion beyond cash.
Depreciation and other non-cash charges help offset losses on the cash flow statement, but not enough to produce positive operating cash flow.
Recent results include acquisition activity, which may help growth but also adds integration risk and cash usage.
Q1 2026 net income was a loss of $10.7 million, versus a loss of $10.1 million in Q4 2025, so the company remains unprofitable.
Operating cash flow was negative $3.3 million in Q1 2026, after being positive $10.3 million in Q4 2025.

Longer-term trend: KIDS has grown revenue from roughly $31.6 million in Q1 2023 to $59.4 million in Q1 2026, nearly doubling in three years. However, losses have also remained persistent, and operating expenses have expanded alongside the business. In other words, OrthoPediatrics is still in growth mode, but not yet converting that growth into consistent bottom-line profitability.

Cash flow is the biggest concern. Q1 2026 showed a net cash decrease of $7.7 million, driven by negative operating and investing cash flows. The company ended Q1 2026 with about $12.2 million in cash and equivalents, down sharply from $44.6 million at Q2 2025 and $16.8 million at Q3 2025, although it still held meaningful short-term investments and restricted cash.

Debt and leverage also matter. Long-term debt was $100.4 million in Q1 2026, up from $73.0 million in Q1 2025. While the balance sheet is not in distress, debt has risen while earnings remain negative, which could keep pressure on future flexibility.

Bottom line: OrthoPediatrics appears to be a company with solid revenue momentum and a manageable balance sheet, but investors should watch for whether growth can finally outpace operating expenses. Until operating income and cash flow turn consistently positive, the stock will likely remain a story about execution rather than profits.

07/07/26 09:52 PM ETAI Generated. May Contain Errors.

OrthoPediatrics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, OrthoPediatrics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

OrthoPediatrics' net income appears to be on an upward trend, with a most recent value of -$39.65 million in 2025, rising from -$7.89 million in 2015. The previous period was -$37.82 million in 2024. See where experts think OrthoPediatrics is headed by visiting OrthoPediatrics' forecast page.

OrthoPediatrics' total operating income in 2025 was -$39.24 million, based on the following breakdown:

Total Gross Profit: $172.66 million
Total Operating Expenses: $211.90 million

Over the last 10 years, OrthoPediatrics' total revenue changed from $31.00 million in 2015 to $236.35 million in 2025, a change of 662.3%.

OrthoPediatrics' total liabilities were at $162.03 million at the end of 2025, a 36.6% increase from 2024, and a 556.5% increase since 2016.

In the past 9 years, OrthoPediatrics' cash and equivalents has ranged from $0.00 in 2021 to $70.78 million in 2019, and is currently $19.56 million as of their latest financial filing in 2025.

Over the last 10 years, OrthoPediatrics' book value per share changed from 0.00 in 2015 to 13.82 in 2025, a change of 1,382.1%.

Related Companies

Financial statements for NASDAQ:KIDS last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OrthoPediatrics (KIDS) Financials

Financials Breakdown Chart

Key Financial Trends

OrthoPediatrics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OrthoPediatrics (KIDS) Financials

Annual Income Statements for OrthoPediatrics

Quarterly Income Statements for OrthoPediatrics

Annual Cash Flow Statements for OrthoPediatrics

Quarterly Cash Flow Statements for OrthoPediatrics

Annual Balance Sheets for OrthoPediatrics

Quarterly Balance Sheets for OrthoPediatrics

Annual Metrics And Ratios for OrthoPediatrics

Quarterly Metrics And Ratios for OrthoPediatrics

Financials Breakdown Chart

Key Financial Trends

OrthoPediatrics Financials - Frequently Asked Questions

When does OrthoPediatrics' financial year end?

How has OrthoPediatrics' net income changed over the last 10 years?

What is OrthoPediatrics' operating income?

How has OrthoPediatrics' revenue changed over the last 10 years?

How much debt does OrthoPediatrics have?

How much cash does OrthoPediatrics have?

How has OrthoPediatrics' book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools